Looking to expand its immunology portfolio, Sanofi has agreed to acquire Blueprint Medicines for a total equity value, including potential CVR payments, of approximately US$9.5 B. The deal will provide Sanofi with access to a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), which is approved in the US and EU for the treatment of advanced and indolent systemic mastocytosis, as well as investigational assets elenestinib and BLU-808. The deal marks yet another M&A deal announced by the French pharma giant as it attempts to rebuild its pipeline following several setbacks in the clinic.